After ten-years of development, Guangzhou International Bio Island (GIBI) is becoming the vital engine of Guangzhou biomedical industry. On August 11, a press conference was held to brief the media on GIBI's achievements over the past ten years and its future development prospects.
Photo: Nicole(intern)
GIBI has been listed as one of the important innovation nodes and one of the first ten valuable innovation parks in Guangzhou in July 2011.
At present, GIBI is home to over 500 biomedical enterprises, including 7 Fortune Global 500 enterprises, 5 headquarters of listed companies, nearly 40 research institutes and 36 drug clinical institutions. It is worth mentioning that GIBI has established cooperation and relationships with four companies on the Pharm Exec's Top 50 Companies 2021 list, including AstraZeneca, Gilead, Merck and Hengrui Pharma.
In May 2021, the Guangzhou Laboratory led by China's top epidemiologist Zhong Nanshan started operation on GIBI, in order to build a base and platform for clinical applications, achievement transformation, industrialization and high level talent.
In the future, the Guangzhou Laboratory will attract more major innovation platforms, promote GIBI to speed up its establishment of a national biomedical policy innovation pilot zone, making it world's top biomedicine and biosafety R&D center.
In addition, the Bioland Laboratory on GIBI focuses on the frontier research of regenerative medicine, tissue and organ remodeling and aims to build an international leading clinical research base as well as promote its AI auxiliary diagnosis system throughout the country.
Now more and more R&D platforms have settled on GIBI, such as the P3 labs of Guangzhou Customs and the National Clinical Research Center for Respiratory Disease.
Over the past three years, the Innovation Center of High-performance Medical Device Industry in the Guangdong-Hong Kong-Macao Greater Bay Area has been working on creating a world leading platform for innovative research and efficient industrial transformation in the field of high-performance medical devices. The center was launched on GIBI during the Third Guangzhou International Bio-Forum in June 2019.
Photo: Nicole(intern)
Other leading enterprises such as AstraZeneca, Danaher, Merck and KingMed Diagnostics are also contributing to GIBI's integration into the global biotechnology innovation landscape.
For example, Sagene Biotech detected the first COVID-19 case in Guangdong at the beginning of the epidemic outbreak, and provided the first key piece of evidence to establish human-to-human transmission of COVID-19 was possible.
AcroImmune Group is committed to developing the world's leading innovative biological drugs for the treatment of cancer and autoimmune diseases, and hasmadethe world’s first major breakthrough in COVID-19 severe case phase 3 therapy.
KingMed Diagnostics has grown into the largest third-party medical testing institution in China.
Burning Rock Biotech Limited is listed on NASDAQ as the country’s first leading enterprise in tumor second-generation gene sequencing, their cancer gene sequencing products are among the best of their kind in the world.
At the same time, GIBI has also built several international cooperation platforms including the Guangzhou Sino-Israel Bio Industry Incubation Center and the UK-China Science Bridges. And it joins hands with with the University of Hong Kong to tackle key problems, furthering its integration into the country’s economic development pattern of China’s "dual circulation" policies.
Author | Nicole(intern)